Serologic studies on schizophrenic patients.
We studied the capacity of sera from schizophrenic patients and from normal blood bank donors to agglutinate sheep erythrocytes coated with extracts of human brain. Passive hemagglutination of coated erythrocytes was obtained with 36.4% of the assayed sera of the schizophrenia patients and with 11% of the control sera. Drug treatment did not seem to play a major role in the reactivity because the patients were either never treated before or a period of several weeks was allowed since treatment until blood was drawn. Furthermore, the analysis of sera obtained by sequential bleedings of patients on drug therapy showed that drugs did not affect the serologic activity.
D000293:Adolescent; D000328:Adult; D001714:Bipolar Disorder / Q000276:immunology; D002421:Caudate Nucleus / Q000276:immunology; D002531:Cerebellum / Q000276:immunology; D002746:Chlorpromazine / Q000627:therapeutic use; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D008168:Lung / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy / Q000276:immunology*; D012686:Septal Nuclei / Q000276:immunology; D013154:Spleen / Q000276:immunology; D014020:Tissue Extracts / Q000276:immunology
D014020:Tissue Extracts; D002746:Chlorpromazine